Latest News for PHGUF
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs.
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PHGUF.
Senate Trading
No Senate trades found for PHGUF.
U.S. House Trading
No House trades found for PHGUF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.